🇺🇸 FDA

Company profile · Sponsor

Xenon

Xenon Pharmaceuticals

XENE · NYSE pharma BURNABY, USA
Pipeline
22
Drugs
0
Patents
8

Quick answer

Xenon (XENE) is a pharma company. headquartered in BURNABY, USA. listed on NYSE. NovaPharmaNews links 22 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker XENE
Exchange NYSE
Company type pharma
Headquarters BURNABY, USA
SEC CIK 0001582313

Pipeline (22)

Search pipeline →

  1. Azetukalner

    Xenon

    Bipolar Depression

    phase 3 small molecule active

    1 trial

  2. Azetukalner

    Xenon

    Major Depressive Disorder

    phase 3 small molecule active

    3 trials

  3. Azetukalner

    Xenon

    Bipolar Disorder

    phase 3 small molecule active

    1 trial

  4. Placebo, XPF-010

    Xenon

    Depressive episodes associated with Bipolar disorder I or II (Bipolar Depression)

    phase 3 small molecule active

    1 trial

  5. XEN1101

    Xenon

    Primary Generalized Tonic-Clonic Seizures

    phase 3 small molecule active

    1 trial

  6. XEN1101

    Xenon

    Focal Epilepsy

    phase 3 small molecule active

    2 trials

  7. XEN1101

    Xenon

    Focal Onset Seizures

    phase 3 small molecule active

    2 trials

  8. XEN496

    Xenon

    Epilepsy

    phase 3 small molecule terminated

    2 trials

  9. XPF-010

    Xenon

    Depressive episodes associated with Bipolar disorder I or II (Bipolar Depression)

    phase 3 small molecule active

    1 trial

  10. XPF-010, Placebo to match XPF-010

    Xenon

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  11. XEN1101 10 mg

    Xenon

    Major Depressive Disorder

    phase 2 small molecule completed

    1 trial

  12. XPF-001

    Xenon

    Dental Pain

    phase 2 small molecule completed

    1 trial

  13. XPF-001

    Xenon

    Primary Erythromelalgia

    phase 2 small molecule completed

    1 trial

  14. XPF-002

    Xenon

    Primary Erythromelalgia

    phase 2 small molecule completed

    1 trial

  15. XPF-002

    Xenon

    Postherpetic Neuralgia

    phase 2 small molecule completed

    1 trial

  16. XPF-005

    Xenon

    Acne Vulgaris

    phase 2 small molecule completed

    1 trial

  17. XPF-010, XPF-008, XEN1101 placebo

    Xenon

    Adult focal (partial onset) epilepsy

    phase 2 small molecule active

    1 trial

  18. 14C-XEN1101

    Xenon

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  19. XEN901

    Xenon

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  20. XPF-001

    Xenon

    Healthy Human Volunteers

    phase 1 small molecule completed

    1 trial

  21. XPF-008

    Xenon

    Healthy Male Volunteers

    phase 1 small molecule completed

    1 trial

  22. XPF-008

    Xenon

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

Patents (8)

Search patents →

  1. US 12319657

    Solid state crystalline forms of a selective potassium channel modulator

    Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12178811

    Methods of treating depressive disorders

    Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12171759

    Methods and uses for treating anhedonia

    Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11957675

    Methods and uses for treating anhedonia

    Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11325902

    Benzenesulfonamide compounds and their use as therapeutic agents

    Expires Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11299490

    Benzenesulfonamide compounds and their use as therapeutic agents

    Expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11203572

    Substituted benzamides and methods of use thereof

    Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11174268

    Benzenesulfonamide compouds and their use as therapeutic agents

    Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Xenon?

Xenon (XENE) is a pharma company. headquartered in BURNABY, USA. listed on NYSE. NovaPharmaNews links 22 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Xenon sponsor?

We track 22 ClinicalTrials.gov-linked programs for Xenon, including Azetukalner and 21 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Xenon company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.